EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Researchers have uncovered the 3D structure of RBP3, a key protein in vision, revealing how it transports retinoids and fatty ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Vascular endothelial growth factor inhibitors (VEGFIs) have transformed treatment paradigms for several malignancies. By ...

Proteins are fundamental biomolecules that perform a broad range of vital functions within the human body. They serve as an essential structural and functional component of cells, tissues and organs ...

Biocon share price has gained 1.6% in one month, but the stock has declined 11% on a year-to-date (YTD) basis. Biocon shares have rallied 23% in one year and more than 46% in two years.

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US ...

Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US ...

A recent study has uncovered a potential breakthrough in treating osteonecrosis of the femoral head (ONFH), a debilitating ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.